Pharmanutra S.p.A.

BIT:PHN Stock Report

Market Cap: €754.5m

Pharmanutra Future Growth

Future criteria checks 5/6

Pharmanutra is forecast to grow earnings and revenue by 22.2% and 10.9% per annum respectively. EPS is expected to grow by 22% per annum. Return on equity is forecast to be 31.5% in 3 years.

Key information

21.7%

Earnings growth rate

22.00%

EPS growth rate

Personal Products earnings growth9.5%
Revenue growth rate11.1%
Future return on equity31.73%
Analyst coverage

Low

Last updated14 Sep 2026

Recent future growth updates

Recent updates

Analysis Article • Nov 29

Why Investors Shouldn't Be Surprised By Pharmanutra S.p.A.'s (BIT:PHN) 26% Share Price Surge

Pharmanutra S.p.A. ( BIT:PHN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
Analysis Article • Nov 27

Here's Why Pharmanutra (BIT:PHN) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 20

Pharmanutra's (BIT:PHN) Dividend Will Be Increased To €1.00

Pharmanutra S.p.A.'s ( BIT:PHN ) dividend will be increasing from last year's payment of the same period to €1.00 on...
Analysis Article • Sep 11

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Pharmanutra S.p.A.'s ( BIT:PHN ) price-to-earnings (or "P/E") ratio of 52.9x might make it look like a strong sell...
Analysis Article • Mar 23

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Pharmanutra S.p.A.'s ( BIT:PHN ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...
Analysis Article • Sep 26

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • May 16

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 11

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Nov 02

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Analysis Article • Aug 03

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysis Article • May 20

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Analysis Article • Apr 19

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Analysis Article • Mar 10

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Pharmanutra (BIT:PHN) has had a great run on the share market with its stock up by a significant 12% over the last...
Analysis Article • Feb 17

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
Analysis Article • Feb 01

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Jan 18

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Could Pharmanutra S.p.A. ( BIT:PHN ) be an attractive dividend share to own for the long haul? Investors are often...
Analysis Article • Jan 04

Is Pharmanutra (BIT:PHN) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 22

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Analysis Article • Dec 08

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Every investor in Pharmanutra S.p.A. ( BIT:PHN ) should be aware of the most powerful shareholder groups. Institutions...
Analysis Article • Nov 23

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Pharmanutra's (BIT:PHN) stock is up by a considerable 20% over the past three months. Given that the market rewards...

Earnings and Revenue Growth Forecasts

BIT:PHN - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282043633393
12/31/20271813128363
12/31/20261552522293
6/30/2026143211519N/A
3/31/2026139211619N/A
12/31/2025132201620N/A
9/30/2025127171014N/A
6/30/202512217812N/A
3/31/2025119162125N/A
12/31/2024116171620N/A
9/30/2024113161923N/A
6/30/2024108141520N/A
3/31/202410111212N/A
12/31/202310113-112N/A
9/30/20239512-512N/A
6/30/20239314-1912N/A
3/31/20238816-1514N/A
12/31/20228315-917N/A
9/30/20227916-519N/A
6/30/202276151019N/A
3/31/202273151420N/A
12/31/202168141520N/A
9/30/202165141316N/A
6/30/202160111215N/A
3/31/202157141315N/A
12/31/202057141012N/A
9/30/202058141111N/A
6/30/20205814711N/A
3/31/2020559N/A9N/A
12/31/2019548N/A12N/A
9/30/2019498N/A8N/A
6/30/2019509N/A9N/A
3/31/2019489N/A8N/A
12/31/2018479N/A6N/A
9/30/2018448N/A6N/A
6/30/2018417N/A6N/A
3/31/2018406N/A6N/A
12/31/2017386N/A6N/A
9/30/2017375N/AN/AN/A
6/30/2017355N/AN/AN/A
3/31/2017344N/AN/AN/A
12/31/2016334N/A6N/A
12/31/2015263N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHN's forecast earnings growth (22.2% per year) is above the savings rate (3.4%).

Earnings vs Market: PHN's earnings (22.2% per year) are forecast to grow faster than the Italian market (10.1% per year).

High Growth Earnings: PHN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PHN's revenue (10.9% per year) is forecast to grow faster than the Italian market (5.7% per year).

High Growth Revenue: PHN's revenue (10.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PHN's Return on Equity is forecast to be high in 3 years time (31.5%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 13:21
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmanutra S.p.A. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anna FrontaniBerenberg
Andrea RandoneIntermonte SIM S.p.A.
Giorgio TavoliniIntermonte SIM S.p.A.